BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.
  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

96 results

Results per page: 10 20 30

Azido impurity in losartan Date: 12. July 2022 Topics: Pharmakovigilanz Type: Risk information

Active substance: losartan

Azido impurity in losartan

Update of Iris version and decision tables available Date: 14. May 2021 Topics: Kodiersysteme Type: News

We published a new version of the Iris software and the associated MUSE files - V5.8.1-Y2021S2 and specV2021SR30-Muse. It includes the updates of unicausal and multicausal tables for 2021.

New Iris version and decision tables available Date: 03. February 2021 Topics: Kodiersysteme Type: News

We published a new version of the Iris software and the associated MUSE files - V5.8.0-Y2021S1 and specV2021SR10-Muse. It includes the unicausal and multicausal tables for 2021. Previous version 5 releases have been tested thoroughly and detected …

Hydroxychloroquine and Chloroquine: Psychiatric disorders Date: 27. November 2020 Topics: Pharmakovigilanz Type: Risk information

Active substance: hydroxychloroquine, chloroquine

Current information about psychiatric disorders for Chloroquine and Hydroxychloroquine.

EU regulators request nitrosamine testing of metformin medicines (CHMP meeting highlights 12-15 October 2020) Date: 16. October 2020 Topics: Pharmakovigilanz Type: Risk information

Active substance: metformin

EU regulators request nitrosamine testing of metformin medicines

Remdesivir (Veklury®): PRAC checks signal for kidney damage Date: 06. October 2020 Topics: Pharmakovigilanz Type: Risk information

Active substance: remdesivir

PRAC has begun reviewing a safety signal for acute renal damage in some COVID-19 patients treated with Veklury® (Remdesivir).

Hydroxychloroquine: Renewed warning of risks when used to treat COVID-19 Date: 02. June 2020 Topics: Pharmakovigilanz Type: Risk information

Active substance: hydroxychloroquine, chloroquine

The European Medicines Agency (EMA) again warns about the risks of using hydroxychloroquine (and chloroquine) to treat COVID-19.

Hormone replacement therapy: PRAC completes review of new information on known breast cancer risk Date: 15. May 2020 Topics: Pharmakovigilanz Type: Risk information

Active substance: substances for hormone replacement therapy

The Committee for Pharmacovigilance Risk Assessment (PRAC) of the EMA recommends updating the current safety information of medicinal products for HRT, in relation to the known increased risk of breast cancer.

Hydroxychloroquine: Risk of serious side effects when used to treat COVID-19 Date: 29. April 2020 Topics: Pharmakovigilanz Type: Risk information

Active substance: hydroxychloroquine, chloroquine

The BfArM informs about the risk of serious side effects when using hydroxychloroquine for the treatment of COVID-19.

Increased ring fractures with vaginal rings Date: 01. April 2020 Topics: Pharmakovigilanz Type: Risk information

Active substance: ethinylestradiol, etonogestrel

The BfArM has received a large number of reports of breaks in the vaginal rings GinoRing® (Exeltis Germany GmbH), Cyclelle® (Hexal AG), VeriAristo® (Aristo Pharma GmbH) and Setlona® (Mylan Germany GmbH), which are used for hormonal …